AC Immune Drug Clears Phase I, Crosses Blood-Brain Barrier

AC Immune's experimental anti-inflammatory therapy, ACI-19764, has achieved a significant milestone with the successful completion of its Phase I first-in-human study in healthy volunteers. The European-based trial confirmed the drug's safety and tolerability across various dose levels, with no severe adverse events reported. A crucial finding was ACI-19764's ability to penetrate the blood-brain barrier, evidenced by its presence in participants' spinal fluid. This CNS penetration is vital for its intended use in neurodegenerative diseases.

Furthermore, early-stage results indicated that ACI-19764 engages its target, showing a dose-dependent effect on the release of the pro-inflammatory cytokine IL-1β. This inhibition of inflammation is theorized to benefit disorders ranging from metabolic to neurological conditions. Following these positive early signals, AC Immune has initiated patient dosing in the Phase Ib portion of the study, focusing on individuals with type 2 diabetes, obesity, and cardiovascular disease risk factors.

The company anticipates releasing comprehensive results from the Phase I/Ib study in the first half of 2027. Analysts have described the initial Phase I data as providing "encouraging validation" of ACI-19764's activity and potential for once-daily efficacy, though they emphasize the program's early stage and the need for further data.